Analysts expect Dr Reddy’s Q1 profit to rise 7% YoY, with 13% revenue growth, driven by domestic and U.S. sales.

• Jefferies sees 11% domestic sales growth; U.S. revenue aided by cancer drug Revlimid’s performance.
• Stock down ~10% YTD; underperforms Nifty 50’s 5.8% gain and Nifty Pharma’s 4.6% drop.
• REDY shares dip ahead of results; 8 of 20 pharma index stocks rated “hold,” rest rated “buy” or better.